CST530 is an inhibitor of apoptosis protein (IAP) antagonist. CST530 is an IAP-type Ligands for E3 Ligase. CST530 binds to the BIR3 domain of IAP and interferes with its function, thereby promoting the ubiquitination and degradation of cIAP1. CST530 can be used to prepare PROTACs.

RMT 5265 (RMT5265) is a potent, small molecule bivalent mimic of Smac, inhibits XIAP and cIAP1/2 through the BIR3 domain.

DEBIO 1143 (Xevinapant, AT-406, SM406, ARRY-334543, D1143) is a potent, orally active Smac mimetic that antagonizes cIAP1, cIAP2 and XIAP with Ki of 66.4, 1.9 and 5.1 nM, respectively.

ARTS mimetic A4 is a small molecule that mimics the function of the pro-apoptotic ARTS (Sept4_i2) protein, binds the ARTS pocket in XIAP-BIR3, but not cIAP1, specifically promotes degradation of XIAP and induces caspase-mediated cell death.

142D6 is a potent, Lys-covalent pan-IAP inhibitor, targets the BIR3 domain of the inhibitor of the apoptosis protein (IAP) family with IC50 of 43/21/21 nM for XIAP/cIAP1/cIAP2, respectively.

APG-1387, a bivalent SMAC mimetic, is an IAP antagonist that can induce proteasomal degradation of IAPs. APG-1387 sensitizes immune-mediated cell apoptosis in cancers. APG-1387 can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma.

YM155 is a potent IAP (inhibitor of apoptosis proteins) inhibitor for survivin with IC50 of 0.54 nM.

4-Methylsalicylic acid is a salicylic acid. 4-Methylsalicylic acid derivative is a selective tissue-nonspecific alkaline phosphatase (TNAP) and intestinal alkaline phosphatase (IAP) inhibitor.

SW IV-52 is a pro-apoptotic small molecule SMAC mimetic and XIAP inhibitor.

SW IV-134 is a sigma-2/SMAC drug conjugate, chemically linked the sigma-2 ligand SW43 to the Smac mimetic SW IV-52.SW IV-134 slowed tumor growth and improved survival in murine models of pancreatic cancer.SW IV-134 significantly reduced tumor burden and improved overall survival in a mouse xenograft model of ovarian cancer without causing significant adverse effects to normal tissues.SW IV-134 induced degradation of cIAP-1 and cIAP-2 leading to NF-қB activation and TNFα-dependent cell death.

AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively).

BV6 induced apoptotic and necrotic cell death in monocytes while T-cells, dendritic cells and macrophages were largely protected against BV6-induced cell death.

SM-433 hydrochlorid, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 hydrochlorid exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2).

XIAP degrader-1, a primary amine tethered small molecule, promotes the degradation of X-linked inhibitor of apoptosis protein (XIAP).

SM-433, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM. (patent WO2008128171A2).

LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells.

A potent, orally bioavailable, dual XIAP/cIAP1 inhibitor with EC50 of 5.1/0.32 nM, respectively.

>98%,Standard References